The Technical Analyst
Obseva SA [OBSV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Obseva SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.102
America/New_York / 22 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11.00 mill |
| EPS: | -0.740 |
| P/E: | -0.138 |
| Earnings Date: | Aug 15, 2023 |
| SharesOutstanding: | 108.02 mill |
| Avg Daily Volume: | 7.95 mill |
| RATING 2023-04-24 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.138 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.138 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0600 - 0.108 ( +/- 28.57%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-04-06 | Loumaye Ernest | Buy | 4 000 000 | Common Shares |
| 2023-02-28 | Loumaye Ernest | Buy | 4 000 000 | Common Shares |
| 2023-02-23 | Brown William Michael | Buy | 250 000 | Employee Stock Option (right to buy) |
| 2023-01-01 | Loumaye Ernest | Sell | 0 | Common Stock |
| 2023-01-01 | Mathers Edward T | Sell | 32 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 76.88 |
| Last 14 transactions |
| Buy: 8 250 000 | Sell: 1 374 140 |
Forecast:
01:40 - $0.103
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.102 (0.00% ) |
| Volume | 8.23 mill |
| Avg. Vol. | 7.95 mill |
| % of Avg. Vol | 103.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OBSV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OBSV
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Latest Press Releases
2024-04-03 01:00:00 - Press Release
Obseva Announces Delisting From Six Swiss Exchange And Exemption From Certain Obligations Associated With The Maintenance Of Listin
Ad hoc announcement pursuant to art. 53 lr of the six swiss exchange geneva, switzerland – april 3, 2024 – obseva sa (six: obsn), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that the regulatory board of six swiss exchange has granted the delisting of the shares of the company (swiss security number 126'004'193 / isin ch1260041939) from six swiss exchange and has exempted the company from certain obligations associated with the maintenance of the listing.
2024-03-19 02:00:00 - Press Release
Obseva Announces Update On Board Of Directors
Ad hoc announcement pursuant to art. 53 lr of the six swiss exchange geneva, switzerland – march 18, 2024 – obseva sa (six: obsn), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that, concurrent to the decision to wind-down the company's operations, catarina edfjÄll, ph.d.
2024-02-28 01:00:00 - Press Release
Obseva Announces Wind-down Of Operations And Notifies Six That It Will Lack The Resources To Establish Audited Ifrs Financial Statements For 2023
Ad hoc announcement pursuant to art. 53 lr of the six swiss exchange geneva, switzerland – 28 february 2024 – obseva sa (six: obsn), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including fabien de ladonchamps, ceo, and notified six swiss exchange's listing authority that there was a substantial risk that it will lack the resources to have financial statements for 2023 prepared under ifrs audited, and that it is as a result likely not going to be able to satisfy the requirements for maintaining its listing on six.
2024-01-31 01:00:00 - Press Release
Geneva Court Grants Temporary Moratorium To Obseva
Ad hoc announcement pursuant to art. 53 lr of the six swiss exchange geneva, switzerland – 31 january 2024 – obseva sa (six: obsn), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in geneva, switzerland.
2023-11-30 01:00:00 - Press Release
Obseva Announces Application For A Moratorium To Facilitate Pivotal Deals
Ad hoc announcement pursuant to art. 53 lr of the six swiss exchange geneva, switzerland – november 30, 2023 – obseva sa (six: obsn), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the board of directors has opted to seek a moratorium from the competent court in geneva, switzerland.
Latest News
2023-03-09 06:00:00 - PennyStocks
What Do Penny Stocks Offer Over Blue Chips?
Why penny stocks might be a better choice for some investors than blue chips The post What Do Penny Stocks Offer Over Blue Chips? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-06 06:00:00 - PennyStocks
The Most Important Penny Stocks Trading Indicators
These indicators can help you to make money with penny stocks The post The Most Important Penny Stocks Trading Indicators appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-05 11:00:00 - PennyStocks
Penny Stocks Trading: How News Plays a Role
Use these tips for making money with penny stocks in 2023 The post Penny Stocks Trading: How News Plays a Role appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-03 08:11:02 - InvestorPlace
Why Is ObsEva (OBSV) Stock Up 93% Today?
ObsEva (NASDAQ: OBSV ) stock is taking off on Friday as investors react to insider buying at the clinical-stage biopharmaceutical company. Ernest Loumaye, a member of the Board of Directors at ObsEva, purchased 4 million shares of OBSV stock on Tuesday.
2023-02-27 08:37:03 - InvestorPlace
Why Is ObsEva (OBSV) Stock Up 61% Today?
ObsEva (NASDAQ: OBSV ) stock is bouncing back on Monday after the company's stock underwent a major dip during the prior day of trading. That crash saw the company's shares fall 50.8% during Friday's normal trading hours.
2023-02-24 10:54:15 - InvestorPlace
Why ObsEva (OBSV) Stock Is Down 36% Today
ObsEva (NASDAQ: OBSV ) is trending on social media, and OBSV stock is tumbling 36% to 10.85 cents. The Swiss biopharmaceutical company announced that it would undertake a major reorganization to preserve its remaining funds, noting that it “is expecting to be delisted from Nasdaq, and intends to deregister from the US Securities and Exchange Commission” ObsEva reported that it would concentrate its efforts on developing its nolasiban drug candidate.
2022-12-01 18:48:29 - Zacks Investment Research
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-08-30 06:00:00 - PennyStocks
Hot Penny Stocks For Your Buy List in September? 3 to Watch
Here's what you need to know about trading penny stocks on August 30th The post Hot Penny Stocks For Your Buy List in September? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-08-03 13:32:19 - Zacks Investment Research
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-07-27 11:45:29 - InvestorPlace
Why Is ObsEva (OBSV) Stock Down 70% Today?
Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning.